0001213900-18-005508.txt : 20180504 0001213900-18-005508.hdr.sgml : 20180504 20180504083028 ACCESSION NUMBER: 0001213900-18-005508 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180504 FILED AS OF DATE: 20180504 DATE AS OF CHANGE: 20180504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Therapix Biosciences Ltd. CENTRAL INDEX KEY: 0001611746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1213 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38041 FILM NUMBER: 18806118 BUSINESS ADDRESS: STREET 1: 4 ARIEL SHARON STREET STREET 2: HASHAHAR TOWER, 16TH FLOOR CITY: GIV?ATAYIM STATE: L3 ZIP: 5320047 BUSINESS PHONE: 972-3-6167055 MAIL ADDRESS: STREET 1: 4 ARIEL SHARON STREET STREET 2: HASHAHAR TOWER, 16TH FLOOR CITY: GIV?ATAYIM STATE: L3 ZIP: 5320047 6-K 1 f6k050418_therapixbiosc.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: May 2018 (Report No. 1)

 

Commission file number: 001- 38041

 

THERAPIX BIOSCIENCES LTD.

(Translation of registrant’s name into English)

 

4 Ariel Sharon Street

HaShahar Tower, 16th Floor

Givatayim 5320047, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒          Form 40-F  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

 

 

 

  

 

On April 30, 2018, Therapix Biosciences Ltd. (the “Company”) notified Belvit Pharma LLC (“Belvit”) of its intent to terminate the Term Sheet dated June 7, 2016 between the Company and Belvit. Accordingly, the Company is discontinuing the development of its ultra-low dose tetrahydrocannabinol, or THC, via sublingual administration. However, the Company intends to continue advancing its ultra-low dose THC therapy for the treatment of mild cognitive impairments, or MCI, utilizing buccal administration of dronabinol,

 

 1 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Therapix Biosciences Ltd.

(Registrant)

     
  By   /s/ Ascher Shmulewitz
  Name:  Ascher Shmulewitz, M.D, Ph.D.
  Title: Chief Executive Officer

 

Date: May 4, 2018

 

 2